Robert E. Ratner
About
Robert E. Ratner is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology.
According to data from OpenAlex, Robert E. Ratner has authored 159 papers receiving a total of 16.6k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Endocrinology, Diabetes and Metabolism, 52 papers in Surgery and 45 papers in Molecular Biology. Recurrent topics in Robert E. Ratner's work include Diabetes Treatment and Management (69 papers), Diabetes Management and Research (57 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (41 papers). Robert E. Ratner is often cited by papers focused on Diabetes Treatment and Management (69 papers), Diabetes Management and Research (57 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (41 papers). Robert E. Ratner collaborates with scholars based in United States, United Kingdom and Canada. Robert E. Ratner's co-authors include Mark Fineman, Jenny Han, Dennis Dong Hwan Kim, Ralph A. DeFronzo, Alain Baron, Sarah Fowler, Robert R. Henry, Bruce W. Bode, Irl B. Hirsch and Vanita R. Aroda and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.
In The Last Decade
Robert E. Ratner
157 papers receiving 15.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Robert E. Ratner United States | 60 | 10.7k | 5.1k | 3.7k | 2.0k | 1.9k | 159 | 16.6k | ||
| Michel Marre France | 66 | 8.7k 0.8× | 3.3k 0.7× | 3.9k 1.1× | 3.8k 1.9× | 2.2k 1.1× | 423 | 17.2k | ||
| Helen M. Colhoun United Kingdom | 65 | 8.8k 0.8× | 8.0k 1.6× | 2.3k 0.6× | 4.2k 2.1× | 1.9k 1.0× | 278 | 19.3k | ||
| Andrzej S. Królewski United States | 63 | 5.8k 0.5× | 3.2k 0.6× | 3.1k 0.9× | 2.5k 1.3× | 3.2k 1.7× | 190 | 15.7k | ||
| Henning Beck‐Nielsen Denmark | 83 | 8.3k 0.8× | 4.6k 0.9× | 8.3k 2.3× | 2.2k 1.1× | 2.7k 1.4× | 447 | 23.2k | ||
| Giorgio Sesti Italy | 67 | 6.9k 0.6× | 3.4k 0.7× | 5.6k 1.5× | 2.7k 1.4× | 1.3k 0.7× | 416 | 15.1k | ||
| Michael W. Steffes United States | 63 | 7.2k 0.7× | 4.2k 0.8× | 2.4k 0.6× | 3.4k 1.7× | 2.8k 1.4× | 154 | 19.7k | ||
| Allan Vaag Denmark | 73 | 6.5k 0.6× | 3.9k 0.8× | 7.7k 2.1× | 1.7k 0.9× | 2.9k 1.5× | 419 | 20.7k | ||
| Paul N. Hopkins United States | 63 | 5.7k 0.5× | 5.0k 1.0× | 2.9k 0.8× | 5.3k 2.7× | 2.1k 1.1× | 295 | 16.2k | ||
| Vivian Fonseca United States | 84 | 15.2k 1.4× | 5.9k 1.2× | 6.1k 1.7× | 4.7k 2.4× | 1.9k 1.0× | 462 | 26.7k | ||
| Alicia J. Jenkins Australia | 61 | 5.0k 0.5× | 2.3k 0.4× | 2.8k 0.8× | 1.9k 0.9× | 1.2k 0.6× | 420 | 14.4k |
Countries citing papers authored by Robert E. Ratner
Since
Specialization
Citations
This map shows the geographic impact of Robert E. Ratner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Ratner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Ratner more than expected).
Fields of papers citing papers by Robert E. Ratner
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Robert E. Ratner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Ratner. The network helps show where Robert E. Ratner may publish in the future.
Co-authorship network of co-authors of Robert E. Ratner
This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Ratner. A scholar is included among the top collaborators of Robert E. Ratner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Ratner. Robert E. Ratner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Adams, Rebecca N., et al.. (2025). Sustained metabolic improvements in a remotely delivered ketogenic nutrition programme for veterans with type 2 diabetes: A 3‐year observational study. Diabetes Obesity and Metabolism. 27(9). 4825–4835.
2.
Athinarayanan, Shaminie J., Rebecca N. Adams, Michelle VanTieghem, et al.. (2022). Impact of the COVID-19 Pandemic on the Effectiveness of a Metabolic Health Telemedicine Intervention for Weight Loss: A Propensity Score Matching Analysis. Frontiers in Public Health. 10. 897099–897099.
3.
Riddle, Matthew C., John B. Buse, Paul W. Franks, et al.. (2020). COVID-19 in People With Diabetes: Urgently Needed Lessons From Early Reports. Diabetes Care. 43(7). 1378–1381.
4.
Herman, William H., Sharon L. Edelstein, Robert E. Ratner, et al.. (2013). Effectiveness and cost-effectiveness of diabetes prevention among adherent participants.. PubMed. 19(3). 194–202.
5.
Zinman, Bernard, J. Hans DeVries, Bruce W. Bode, et al.. (2013). Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. The Lancet Diabetes & Endocrinology. 1(2). 123–131.
6.
Shah, Bimal R., Mary Jude Cox, Silvio E. Inzucchi, et al.. (2013). A quantitative measure of diabetes risk in community practice impacts clinical decisions: The PREVAIL initiative. Nutrition Metabolism and Cardiovascular Diseases. 24(4). 400–407.
7.
Aroda, Vanita R., Jason Brett, Naum Khutoryansky, & Robert E. Ratner. (2012). Identifying Predictors of Response to Liraglutide in Type 2 Diabetes Using Recursive Partitioning Analysis. Canadian Journal of Diabetes. 36(5). S45–S45.
8.
Sullivan, Shannon D. & Robert E. Ratner. (2011). Should the Metabolic Syndrome Patient with Prediabetes Be Offered Pharmacotherapy?. Current Diabetes Reports. 11(2). 91–98.
9.
Garber, A. J., Robert R. Henry, Robert E. Ratner, et al.. (2010). Liraglutide, a once‐daily human glucagon‐like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 13(4). 348–356.
10.
Ratner, Robert E., Michael A. Nauck, Christoph Kapitza, et al.. (2010). Safety and tolerability of high doses of taspoglutide, a once‐weekly human GLP‐1 analogue, in diabetic patients treated with metformin: a randomized double‐blind placebo‐controlled study1,2. Diabetic Medicine. 27(5). 556–562.
11.
Silverman, Angela, Marie Russell, Mihriye Mete, et al.. (2009). Stop Atherosclerosis in Native Diabetics Study (SANDS): Baseline Characteristics of the Randomized Cohort. Digital Scholarship - UNLV (University of Nevada Reno). 3(1). 3.
12.
Newcomer, John W., Robert E. Ratner, Jan W. Eriksson, et al.. (2009). A 24-Week, Multicenter, Open-Label, Randomized Study to Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone. The Journal of Clinical Psychiatry. 70(4). 487–499.
13.
Howard, Barbara V., Mary J. Roman, Richard B. Devereux, et al.. (2008). Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial. Obstetrical & Gynecological Survey. 63(8). 512–513.
14.
Garber, Alan J., Robert R. Henry, Robert E. Ratner, et al.. (2008). Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. The Lancet. 373(9662). 473–481.
15.
Fleg, Jerome L., Mihriye Méte, Barbara V. Howard, et al.. (2008). Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes. Journal of the American College of Cardiology. 52(25). 2198–2205.
16.
Schwartz, Sherwyn, Robert E. Ratner, Dennis Dong Hwan Kim, et al.. (2008). Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: A randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clinical Therapeutics. 30(5). 858–867.
17.
Wackers, Frans J. Th., Deborah Chyun, Lawrence H. Young, et al.. (2007). Resolution of Asymptomatic Myocardial Ischemia in Patients With Type 2 Diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study. Diabetes Care. 30(11). 2892–2898.
18.
DeFronzo, Ralph A., et al.. (2004). Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetologia. 47.
19.
Hollander, Priscilla, Robert E. Ratner, Mark Fineman, et al.. (2003). Addition of pramlintide to insulin therapy lowers HbA 1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obesity and Metabolism. 5(6). 408–414.
20.
Ratner, Robert E.. (2001). Glycemic control in the prevention of diabetic complications. Clinical cornerstone. 4(2). 24–37.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Michel Marre Breakdown of academic impact, for papers by Helen M. Colhoun Breakdown of academic impact, for papers by Andrzej S. Królewski Breakdown of academic impact, for papers by Henning Beck‐Nielsen Breakdown of academic impact, for papers by Giorgio Sesti Breakdown of academic impact, for papers by Michael W. Steffes Breakdown of academic impact, for papers by Allan Vaag Breakdown of academic impact, for papers by Paul N. Hopkins Breakdown of academic impact, for papers by Vivian Fonseca Breakdown of academic impact, for papers by Alicia J. Jenkins